Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus

Histopathology

Volumn 46, Issue 6, 2005, Pages 642-648

  Lörinc, Ester ^a   Jakobsson, B ^b   Landberg, G ^c   Veress, B ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Barrett's oesophagus; Interobserver agreement; K167; p53; Proliferation

Indexed keywords

EOSIN; HEMATOXYLIN; KI 67 ANTIGEN; PROTEIN P53;

ARTICLE; BARRETT ESOPHAGUS; CELL NUCLEUS; CELL PROLIFERATION; DISEASE SEVERITY; DYSPLASIA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; SWEDEN; UNIVERSITY HOSPITAL;

BARRETT ESOPHAGUS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20644458561     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02139.x     Document Type: Article

References (24)

1. Haggitt RC. Barrett's esophagus, dysplasia and adenocarcinoma. Hum. Pathol. 1994; 25: 982-993.
2. Riddell RH. Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Am. J. Gastroenterol. 1996; 91: 864-872.
3. Jankowski JA, Wright NA, Meltzer SJ et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Pathol. 1999; 154: 965-973.
4. Reid BJ, Haggitt RC, Rubin CE et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 1988; 19: 166-178.
5. Sagan C, Fléjou JF, Diebold MD et al. Reproductibilité des critères histologiques de dysplasie sur muqueuse de Barrett. Gastroenterol. Clin. Biol. 1994; 18: 31-34.
6. Skacel M, Petras RE, Gramlich TL et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol. 2000; 95: 3383-3387.
7. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum. Pathol. 2001; 32: 368-378.
8. Ormsby AH, Petras RE, Henricks WH et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51: 671-676.
9. Khan S, Do KA, Kuhnert P et al. Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: an endoscopic study. Pathology 1998; 30: 136-140.
10. Skacel M, Petras RE, Rybicki LA et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am. J. Gastroenterol. 2002; 97: 2508-2513.
11. Fléjou JF, Potet F, Muzeau F et al. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J. Clin. Pathol. 1993; 46: 330-333.
12. Giménez A, de Haro LM, Parrilla P et al. Immunohistochemical detection of p53 protein could improve the management of some patients with Barrett's esophagus and mild histologic alteration. Arch. Pathol. Lab. Med. 1999; 123: 1260-1263.
13. Rioux-Leclercq N, Turlin B, Sutherland F et al. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus. Oncol. Rep. 1999; 6: 877-882.
14. Whittles CE, Biddlestone LR, Burton A et al. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. J. Pathol. 1999; 187: 535-540.
15. van Sandick JW, Baak JPA, van Lanschot JJB et al. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J. Pathol. 2000; 190: 177-183.
16. Halm U, Tannapfel A, Breitung B et al. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Hepatogastroenterology 2000; 47: 962-966.
17. Weston AP, Banerjee SK, Sharma P et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am. J. Gastroenterol. 2001; 96: 1355-1362.
18. Bian YS, Osterheld MC, Bosman FT et al. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod. Pathol. 2001; 14: 397-403.
19. Hong MK, Laskin WB, Herman BE et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995; 75: 423-429.
20. Rice TW, Goldblum JR, Falk GW et al. p53 immunoreactivity in Barrett's metaplasia, dysplasia and carcinoma. J. Thorac. Cardiovasc. Surg. 1994; 108: 1132-1137.
21. Baak JPA, ten Kate FJW, Offerhaus GJA et al. Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies. J. Clin. Pathol. 2002; 55: 910-916.
22. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's esophagus. Lancet North Am. Ed. 2002; 360: 1587-1589.
23. Going JJ, Keith WN, Neilson L et al. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 2002; 50: 373-377.
24. Younes M, Ertan A, Lechago LV et al. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig. Dis. Sci. 1997; 42: 697-701.